{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:03:27Z","timestamp":1785528207114,"version":"3.56.0"},"reference-count":229,"publisher":"Elsevier","isbn-type":[{"value":"9780323899413","type":"print"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/bs.ircmb.2021.02.008","type":"book-chapter","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T23:08:49Z","timestamp":1644448129000},"page":"83-124","source":"Crossref","is-referenced-by-count":20,"title":["Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.ircmb.2021.02.008_bb0010","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/0008-5472.CAN-09-3783","article-title":"Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias","volume":"70","author":"Abdel-Wahab","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0015","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.hoc.2012.07.006","article-title":"Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms","volume":"26","author":"Abdel-Wahab","year":"2012","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0020","first-page":"S215","article-title":"KRT-232, a first-in-class, murine double minute 2 inhibitor (MDM2i), for myelofibrosis (MF) relapsed or refractory (R\/R) to Janus-associated kinase inhibitor (JAKi) treatment","volume":"4","author":"Al-Ali","year":"2020","journal-title":"HemaSphere"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0025","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.bbmt.2013.10.027","article-title":"Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation","volume":"20","author":"Alchalby","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0030","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/blood-2015-09-671172","article-title":"Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms","volume":"127","author":"Araki","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0035","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/leu.2017.298","article-title":"Fibrotic progression in polycythemia vera is associated with early concomitant driver-mutations besides JAK2","volume":"32","author":"Bartels","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0040","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/s41375-019-0668-5","article-title":"Mutations associated with age-related clonal hematopoiesis in PMF patients with rapid progression to myelofibrosis","volume":"34","author":"Bartels","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0045","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/ejh.13579","article-title":"Combination of myeloproliferative neoplasm driver gene activation of splice factor or epigenetic modifier genes increases risk of rapid blastic progression","volume":"106","author":"Bartels","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb1114","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/ejh.13579","article-title":"Combination of myeloprolifeartive neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression","volume":"106","author":"Bartels","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0050","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0055","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.1365-2141.2008.07560.x","article-title":"Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones","volume":"144","author":"Beer","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0060","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2009-08-236596","article-title":"Two routes to leukemic transformation after a JAK2 mutation\u2013positive myeloproliferative neoplasm","volume":"115","author":"Beer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0065","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1002\/cncr.31986","article-title":"Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia","volume":"125","author":"Benton","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0070","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/cncr.29842","article-title":"The evolution and clinical relevance of prognostic classification systems in myelofibrosis","volume":"122","author":"Bose","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0075","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s12185-019-02758-z","article-title":"Mutational profiling in myelofibrosis: implications for management","volume":"111","author":"Bose","year":"2020","journal-title":"Inter. J. Hematol."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0080","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1080\/10428194.2017.1283032","article-title":"Pathways and mechanisms of venetoclax resistance","volume":"58","author":"Bose","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb1100","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1038\/s41375-020-0778-0","article-title":"A phase 1\/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia","volume":"34","author":"Bose","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0085","series-title":"The MD Anderson Manual of Medical Oncology","article-title":"Philadelphia chromosome-negative myeloproliferative neoplasms (Chapter 6)","author":"Bose","year":"2021"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0090","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1182\/blood-2005-12-013748","article-title":"Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation","volume":"108","author":"Campbell","year":"2006","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0095","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.ccell.2018.10.008","article-title":"JARID2 functions as a tumor suppresor in myeloid neoplasms by repressing self-renewal in hematopoietic progenitor cells","volume":"34","author":"Celik","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0100","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.95","article-title":"Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors","volume":"5","author":"Cerquozzi","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0105","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2015-11-681932","article-title":"Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants","volume":"127","author":"Chachoua","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0110","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm.3788","article-title":"Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia","volume":"21","author":"Chan","year":"2015","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.02.008_bb0115","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1182\/asheducation-2014.1.268","article-title":"How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms","volume":"2014","author":"Chen","year":"2014","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0120","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1182\/bloodadvances.2020001528","article-title":"Outcome of patients with IDH1\/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors","volume":"4","author":"Chifotides","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0125","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1182\/blood.V128.22.1940.1940","article-title":"Survival outcome of patients with acute myeloid leukemia transformed from myeloproliferative neoplasms","volume":"128","author":"Chihara","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0130","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1182\/bloodadvances.2020001503","article-title":"Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML","volume":"4","author":"Choe","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0135","doi-asserted-by":"crossref","first-page":"E202","DOI":"10.1002\/ajh.25146","article-title":"Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia","volume":"93","author":"Chyla","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0140","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1182\/bloodadvances.2020002175","article-title":"RAS\/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features","volume":"4","author":"Coltro","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0145","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood.2019001113","article-title":"Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population","volume":"134","author":"Cordua","year":"2019","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0150","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/leu.2009.169","article-title":"Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias","volume":"24","author":"Couronn\u00e9","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0155","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-020-00376-1","article-title":"New directions for emerging therapies in acute myeloid leukemia: the next chapter","volume":"10","author":"Daver","year":"2020","journal-title":"Blood Cancer J."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0160","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0165","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/bjh.14269","article-title":"Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera","volume":"175","author":"Delic","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0170","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0175","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0180","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-Day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0185","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0190","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/nature20131","article-title":"Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment","volume":"539","author":"Dong","year":"2016","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0195","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2019000943","article-title":"Leukemia secondary to myeloproliferative neoplasms","volume":"136","author":"Dunbar","year":"2020","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb1111","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.hoc.2021.01.001","article-title":"Epigenetic dysregulation of myeloprolifeartive neoplasms","volume":"35","author":"Dunbar","year":"2021","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0200","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/2159-8290.CD-15-1434","article-title":"mutant Calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation","volume":"6","author":"Elf","year":"2016","journal-title":"Cancer Disc."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0205","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0210","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41408-021-00487-3","article-title":"Superior efficacy of co-targeting GFI1\/KDM1A and BRD4 against AML and post-MPN secondary AML cells","volume":"11","author":"Fiskus","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0215","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1111\/bjh.17084","article-title":"Venetoclax plus hypomethylating agent in blast-phase myeloproliferative neoplasm: preliminary experience with 12 patients","volume":"191","author":"Gangat","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0220","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ajh.26186","article-title":"Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases","volume":"96","author":"Gangat","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb1116","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1080\/10428194.2020.1869961","article-title":"Azacitidine and venetoclax for the treatment of accelerated and blast phase myeloproliferative neoplasms and chronic myelomonocytic leukemia: a case series","volume":"62","author":"Garcia-Horton","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0225","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0230","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMc0910063","article-title":"Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms","volume":"362","author":"Green","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0235","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3324\/haematol.2014.113845","article-title":"Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms","volume":"102","author":"Grinfeld","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0240","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0245","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1158\/2159-8290.CD-19-0152","article-title":"Loss of EZH2 reprograms BCAA metabolism to drive leukemic transformation","volume":"9","author":"Gu","year":"2019","journal-title":"Cancer Disc."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0250","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","article-title":"Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele","volume":"114","author":"Guglielmelli","year":"2009","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0255","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","article-title":"EZH2 mutational status predicts poor survival in myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0260","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2014.76","article-title":"The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients","volume":"28","author":"Guglielmelli","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb1109","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1038\/bcj.2015.90","article-title":"Validation of the differential prognostic impact of type 1\/type 1-like versus type 2\/type 2-like CALR mutations in myelofibrosis","volume":"5","author":"Guglielmelli","year":"2015","journal-title":"Blood Cancer J."},{"issue":"Suppl. 1","key":"10.1016\/bs.ircmb.2021.02.008_bb0265","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1182\/blood-2019-129094","article-title":"Involvement of RUNX1 pathway is a common event in leukemic transformation of chronic myeloproliferative neoplasms","volume":"134","author":"Guglielmelli","year":"2019","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0270","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.ajpath.2017.03.009","article-title":"Megakaryocytes in myeloproliferative neoplasms have unique somatic mutations","volume":"187","author":"Guo","year":"2017","journal-title":"Am. J. Pathol."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0275","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/s41375-018-0347-y","article-title":"ASXL1 alteration cooperates with JAK2 V617F to accelerate myelofibrosis","volume":"33","author":"Guo","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0280","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.1182\/bloodadvances.2020002727","article-title":"Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase","volume":"4","author":"Gupta","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0285","series-title":"Navitoclax and ruxolitinib for patients with myelofibrosis and JAK inhibitor experience: response duration in Phase 2 study. In: 2021 European Hematology Association Congress (EHA2021), Abstract EP1076","author":"Harrison","year":"2021"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0290","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJMc1012718","article-title":"p53 Lesions in leukemic transformation","volume":"364","author":"Harutyunyan","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb1113","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.3390\/cancers12082216","article-title":"Splicing anomalies in myeloproliferative neoplasms: paving the way for new therapeutic venues","volume":"12","author":"Hautin","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0295","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s11899-013-0154-5","article-title":"Acute myeloid leukemia following a myeloproliferative neoplasm: clinical characteristics, genetic features and effects of therapy","volume":"8","author":"Heaney","year":"2013","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0300","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00277-017-3211-7","article-title":"Bone marrow findings in blast phase of polycythemia vera","volume":"97","author":"Hidalgo L\u00f3pez","year":"2018","journal-title":"Ann. Hematol."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0305","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1182\/blood-2015-06-652941","article-title":"Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms","volume":"128","author":"Hinds","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb1108","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-021-00497-1","article-title":"Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm","volume":"11","author":"Issa","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0310","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.3390\/ijms20081839","article-title":"Blast transformation in myeloproliferative neoplasms: risk factors, biological findings, and targeted therapeutic options","volume":"20","author":"Iurlo","year":"2019","journal-title":"Inter. J. Mol. Sci."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0315","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V114.22.435.435","article-title":"Deletions of the transcription factor Ikaros in myeloproliferative neoplasms at transformation to acute myeloid leukemia","volume":"114","author":"J\u00e4ger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0320","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.hoc.2020.12.008","article-title":"Accelerated and blast phase myeloproliferative neoplasms","volume":"35","author":"Jain","year":"2020","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0325","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0330","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2008.6","article-title":"Evidence suggesting the presence of a stem cell clone anteceding the acquisition of the JAK2 V617F mutation","volume":"22","author":"Jamal","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0335","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0340","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1158\/2159-8290.CD-18-1138","article-title":"Cytokine-regulated phosphorylation and activation of TET2 by JAK2 in hematopoiesis","volume":"9","author":"Jeong","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0345","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1182\/blood-2014-04-555508","article-title":"Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator","volume":"125","author":"Kameda","year":"2015","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0350","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0355","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/cncr.33477","article-title":"Acute myeloid leukemia: treatment and research outlook for 2021 and the MD Anderson approach","volume":"127","author":"Kantarjian","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0360","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/2040620717731549","article-title":"Biological and clinical implications of telomere disfunction in myeloid malignacies","volume":"8","author":"Kishtagari","year":"2017","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0365","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0370","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","article-title":"JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response","volume":"5","author":"Kleppe","year":"2015","journal-title":"Cancer Disc."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0375","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","article-title":"Dual targeting of oncogenic activativation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms","volume":"33","author":"Kleppe","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0380","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1038\/cdd.2012.88","article-title":"MCL-1 and Bcl-xL regulate Bak\/Bax-dependent apoptosis of the megakaryocytic lineage at multistages","volume":"19","author":"Kodama","year":"2012","journal-title":"Cell Death Differ."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0385","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0390","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1038\/s41375-020-0949-z","article-title":"MDM2 inhibition: an important step forward in cancer therapy","volume":"34","author":"Konopleva","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0395","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0400","series-title":"2021 European Hematology Association Congress (EHA2021)","article-title":"Clinical benefit of pelabresib (CPI-0610) in combination with ruxolitinib in JAK inhibitor treatment na\u00efve myelofibrosis patients: interim efficacy subgroup analysis from Arm 3 of MANIFEST Phase 2 study","author":"Kremyanskaya","year":"2021"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0405","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/leu.2017.230","article-title":"Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status","volume":"32","author":"Kubesova","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0410","series-title":"2021 European Hematology Association Congress (EHA2021)","article-title":"A Phase Ib\/IIb study of ivosidenib with venetoclax +\/- azacitidine in IDH1-mutated myeloid malignancies","author":"Lachowiez","year":"2021"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0415","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.leukres.2018.05.004","article-title":"Outcomes and predictors of survival in blast phase myeloproliferative neoplasms","volume":"70","author":"Lancman","year":"2018","journal-title":"Leuk. Res."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0420","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/bloodadvances.2018015875","article-title":"Targeted next-generation sequencing in blast phase myeloproliferative neoplasms","volume":"2","author":"Lasho","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0425","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1158\/1078-0432.CCR-12-2087","article-title":"The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia","volume":"19","author":"Lee","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0430","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0435","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","article-title":"DNMT3A mutations in acute myeloid leukemia","volume":"363","author":"Ley","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0440","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1182\/blood-2007-09-111971","article-title":"Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2 V617F mutations","volume":"111","author":"Li","year":"2008","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0445","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s11899-018-0491-5","article-title":"Leukemic transformation of myeloproliferative neoplasms: therapeutic and genomic considerations","volume":"13","author":"Li","year":"2018","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0450","doi-asserted-by":"crossref","first-page":"27696","DOI":"10.1038\/srep27696","article-title":"Targeting MCL-1\/BCL-XL forestalls the acquisition of resistance to ABT-199 in acute myeloid leukemia","volume":"6","author":"Lin","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0455","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0460","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0465","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1136\/jclinpath-2015-203177","article-title":"Megakaryocytic hyperplasia in myeloproliferative neoplasms is driven by disordered proliferative, apoptotic and epigenetic mechanisms","volume":"69","author":"Malherbe","year":"2016","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0470","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3390\/jcm10030436","article-title":"Acute myeloid leukemia evolving from myeloproliferative neoplasms: many sides of a challenging disease","volume":"10","author":"Mannelli","year":"2021","journal-title":"J Clin. Med."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0475","first-page":"405","article-title":"Management of advanced phase myeloproliferative neoplasms","volume":"17","author":"Marcellino","year":"2019","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0480","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1182\/bloodadvances.2018024018","article-title":"Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53","volume":"2","author":"Marcellino","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0485","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1158\/2159-8290.CD-20-1353","article-title":"LKB1\/STK11 is a tumor suppressor in the progression of myeloproliferative neoplasms","volume":"11","author":"Marinaccio","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0490","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1182\/blood-2015-11-679571","article-title":"Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis","volume":"127","author":"Marty","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0495","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2018-04-846626","article-title":"A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis","volume":"132","author":"Masarova","year":"2018","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0500","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1002\/cncr.33094","article-title":"Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era","volume":"126","author":"Masarova","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0505","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1182\/bloodadvances.2020003934","article-title":"Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs","volume":"5","author":"Masarova","year":"2021","journal-title":"Blood Adv."},{"issue":"Suppl. 1","key":"10.1016\/bs.ircmb.2021.02.008_bb0510","first-page":"43","article-title":"A randomized open-label, phase 3 study to evaluate imetelstat versus best available therapy (BAT) in patients with intermediate-2 or high-risk myelofibrosis (MF) refractory to Janus kinase inhibitor","volume":"136","author":"Mascarenhas","year":"2020","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0515","first-page":"1084","article-title":"CPI-0610, a Bromodomain and Extraterminal Domain Protein (BET) inhibitor, in combination with ruxolitinib, in JAK inhibitor treatment na\u00efve myelofibrosis patients: update from MANIFEST phase 2 study","volume":"4","author":"Mascarenhas","year":"2020","journal-title":"HemaSphere"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0525","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1182\/bloodadvances.2020002119","article-title":"Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase","volume":"4","author":"Mascarenhas","year":"2020","journal-title":"Blood Adv."},{"issue":"Suppl. 1","key":"10.1016\/bs.ircmb.2021.02.008_bb0530","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood-2020-134262","article-title":"An open-label, global, multicenter phase 1b\/2 study of KRT-232, a first-in-class, oral small-molecule inhibitor of murine double minute 2 (MDM2), combined with ruxolitinib in patients who have myelofibrosis and a suboptimal response to ruxolitinib","volume":"136","author":"Mascarenhas","year":"2020","journal-title":"Blood"},{"issue":"26","key":"10.1016\/bs.ircmb.2021.02.008_bb1107","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1200\/JCO.20.02864","article-title":"Randomized, single-blind, multicenter phase II study of two doses of imetelstat in relapsed or refractory myelofibrosis","volume":"39","author":"Mascarenhas","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0535","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1172\/JCI94516","article-title":"JAK2\/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition","volume":"128","author":"McKenney","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0540","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.celrep.2015.02.005","article-title":"Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis","volume":"10","author":"McKerrell","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0545","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1182\/bloodadvances.2017007047","article-title":"JAK2 V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kinetics","volume":"1","author":"McKerrell","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0550","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1182\/bloodadvances.2018021469","article-title":"The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes","volume":"2","author":"McNamara","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0555","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/leu.2016.275","article-title":"Isocitrate dehydrogenase mutations in myeloid malignancies","volume":"31","author":"Medeiros","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb1115","series-title":"2020 European Hematology Association Congress (EHA2020)","article-title":"Exome sequencing of paired MPN and blast phase shows an accumulation of splicing and chromatin modifying gene mutations, clonal evolution and gain of RAS pathway mutations during progression","author":"Meggendorfer","year":"2020"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0560","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood-2004-07-2864","article-title":"Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases","volume":"105","author":"Mesa","year":"2005","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0565","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.leukres.2006.12.002","volume":"31","author":"Mesa","year":"2007","journal-title":"Leuk. Res."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0570","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s12185-012-1235-2","article-title":"Genetic and epigenetic alterations of myeloproliferative neoplasms","volume":"97","author":"Milosevic","year":"2013","journal-title":"Int. J. Hematol."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0575","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/ajh.23309","article-title":"Clinical significance of genetic aberrations in secondary acute myeloid leukemia","volume":"87","author":"Milosevic","year":"2012","journal-title":"Am. J. Hematol."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0580","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1038\/leu.2017.78","article-title":"Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis","volume":"31","author":"Mosoyan","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0585","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41408-018-0095-2","article-title":"Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis","volume":"8","author":"Mudireddy","year":"2018","journal-title":"Blood Cancer J."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0590","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","article-title":"Physiological JAK2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells","volume":"17","author":"Mullally","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0595","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1182\/blood-2012-01-402396","article-title":"Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of JAK2 V617F-mediated polycythemia vera","volume":"120","author":"Mullally","year":"2012","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0600","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41467-019-13892-x","volume":"11","author":"Mylonas","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0605","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/onc.2011.313","article-title":"JAK2 V617F negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms","volume":"31","author":"Nakatake","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0610","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0615","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.3324\/haematol.2015.129510","article-title":"DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype","volume":"100","author":"Nangalia","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0620","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0625","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/leu.2016.32","article-title":"Thrombopoietin receptor is required for the oncogenic function of CALR mutants","volume":"30","author":"Nivarthi","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0630","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1182\/blood-2018-03-785907","article-title":"How I treat the blast phase of Philadelphia chromosome\u2013negative myeloproliferative neoplasms","volume":"132","author":"Odenike","year":"2018","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0635","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0640","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/hon.2737","article-title":"Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: real-world data","volume":"38","author":"Palandri","year":"2020","journal-title":"Hematol. Oncol."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0645","first-page":"1243","article-title":"Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis","volume":"126","author":"Palandri","year":"2020"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0650","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Disc."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0655","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1182\/bloodadvances.2019001245","article-title":"Clinical developments in epigenetic-directed therapies in acute myeloid leukemia","volume":"4","author":"Pan","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0660","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/leu.2010.77","article-title":"IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms","volume":"24","author":"Pardanani","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0665","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0670","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1111\/bjh.16709","article-title":"Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib","volume":"190","author":"Patel","year":"2020","journal-title":"Br. J Haematol."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb1112","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2015-03-633404","article-title":"Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib","volume":"126","author":"Patel","year":"2015","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb9000","first-page":"1443","article-title":"on behalf of the French Intergroup of Myeloproliferative Neoplasms, 2021. Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study","volume":"5","author":"Paz","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0675","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3324\/haematol.2013.084160","article-title":"Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms","volume":"98","author":"P\u00e9rez","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0680","doi-asserted-by":"crossref","first-page":"10978","DOI":"10.1111\/jcmm.15730","article-title":"Bcl-xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms","volume":"24","author":"Petiti","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0685","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0690","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1182\/blood-2008-01-134114","article-title":"JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders","volume":"112","author":"Plo","year":"2008","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0695","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/bloodadvances.2019000937","article-title":"Venetoclax for AML: changing the treatment paradigm","volume":"3","author":"Pollyea","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0700","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1038\/s41375-019-0472-2","article-title":"Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia","volume":"33","author":"Pollyea","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0705","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood-2013-01-480970","article-title":"Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms","volume":"122","author":"Przychodzen","year":"2013","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0710","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ajh.22257","article-title":"Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies","volume":"87","author":"Puda","year":"2012","journal-title":"Am. J. Hematol."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0715","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1158\/1078-0432.CCR-12-0284","article-title":"Molecular pathways: JAK\/STAT pathway: mutations, inhibitors, and resistance","volume":"19","author":"Quint\u00e1s-Cardama","year":"2013","journal-title":"Clinical Cancer Res."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0720","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nrd3264","article-title":"Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond","volume":"10","author":"Quint\u00e1s-Cardama","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0725","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/MOH.0000000000000017","article-title":"Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm","volume":"21","author":"Rampal","year":"2014","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0730","doi-asserted-by":"crossref","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","article-title":"Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms","volume":"111","author":"Rampal","year":"2014","journal-title":"Proc. Natl. Acad. Sci U. S. A."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0735","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0740","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/bloodadvances.2018019661","article-title":"Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms","volume":"2","author":"Rampal","year":"2018","journal-title":"Blood Adv."},{"issue":"Suppl. 1","key":"10.1016\/bs.ircmb.2021.02.008_bb0745","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood-2020-140186","article-title":"LSD1 inhibitor CPI-482 shows efficacy and prolongs survival in mouse models of AML and post-MPN AML in the context of constitutive JAK-STAT pathway activation","volume":"136","author":"Rampal","year":"2020","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0750","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.2019002140","article-title":"Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia","volume":"135","author":"Roboz","year":"2020","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0755","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3324\/haematol.2016.149765","article-title":"An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis","volume":"102","author":"Rozovski","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0760","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0765","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/leu.2016.260","article-title":"BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells","volume":"31","author":"Saenz","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0770","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1038\/leu.2016.393","article-title":"Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s)AML cells","volume":"31","author":"Saenz","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0775","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s41375-018-0334-3","article-title":"Targeting nuclear \u03b2-catenin as therapy for post-myeloproliferative neoplasm secondary AML","volume":"33","author":"Saenz","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0780","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood.2019002922","article-title":"Mechanistic basis and efficacy of targeting \u03b2-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors","volume":"135","author":"Saenz","year":"2020","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0785","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41375-019-0603-9","article-title":"Prognostic impact of RAS-pathway mutations in patients with myelofibrosis","volume":"34","author":"Santos","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0790","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1084\/jem.20151121","article-title":"The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition","volume":"213","author":"Sashida","year":"2016","journal-title":"J. Exper. Med."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0795","doi-asserted-by":"crossref","first-page":"100716","DOI":"10.1016\/j.blre.2020.100716","article-title":"Management of challenging myelofibrosis after JAK inhibitor failure and\/or progression","volume":"42","author":"Scherber","year":"2020","journal-title":"Blood Rev."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0800","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-019-0236-2","article-title":"Myelofibrosis in 2019: moving beyond JAK2 inhibition","volume":"9","author":"Schieber","year":"2019","journal-title":"Blood Cancer J."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0805","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00277-017-3193-5","article-title":"Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up","volume":"97","author":"Sen\u00edn","year":"2018","journal-title":"Ann. Hematol."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0810","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/bjh.17423","article-title":"Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era","volume":"193","author":"Shah","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0815","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1159\/000512929","article-title":"Accelerated phase of myeloproliferative neoplasms","volume":"144","author":"Shahin","year":"2021","journal-title":"Acta Haematol."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0820","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/aps.2017.7","article-title":"Structure of the PRC2 complex and application to drug discovery","volume":"38","author":"Shi","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0825","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20151136","article-title":"Loss of Ezh2 synergizes with JAK2 V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis","volume":"213","author":"Shimizu","year":"2016","journal-title":"J. Exper. Med."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0830","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/2159-8290.CD-19-1011","article-title":"Advances in the treatment of acute myeloid leukemia: new drugs and new challenges","volume":"10","author":"Short","year":"2020","journal-title":"Cancer Disc."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0835","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJM199802263380902","article-title":"Expression of Bcl-x in erythroid precursors from patients with polycythemia vera","volume":"338","author":"Silva","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0840","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.exphem.2015.06.007","article-title":"Pathogenesis of myeloproliferative neoplasms","volume":"43","author":"Skoda","year":"2015","journal-title":"Exper. Hematol."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb1110","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.3390\/cancers12082194","article-title":"Next generation sequencing in MPNs. Lessons from the past and prospects for use as predictors of prognosis and treatment responses","volume":"12","author":"Skov","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0845","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.leukres.2010.07.042","article-title":"Dynamics of telomere's length and telomerase activity in Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"35","author":"Spanoudakis","year":"2011","journal-title":"Leuk. Res."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0850","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/leu.2011.77","article-title":"DNMT3A mutations in myeloproliferative neoplasms","volume":"25","author":"Stegelmann","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0855","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0860","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/blood-2018-08-869008","article-title":"Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib","volume":"133","author":"Stein","year":"2019","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0865","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1016\/j.bbmt.2016.09.017","volume":"22","author":"Takagi","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0870","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2008-02-138230","article-title":"The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0875","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1200\/JCO.2009.22.8833","article-title":"Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis","volume":"27","author":"Tam","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0880","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/gcc.22784","article-title":"Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies","volume":"58","author":"Taylor","year":"2019","journal-title":"Genes, Chromosomes Cancer"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0885","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0890","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/leu.2011.92","article-title":"Mutations galore in myeloproliferative neoplasms: would the real Spartacus please stand up?","volume":"25","author":"Tefferi","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0895","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","article-title":"Myeloproliferative neoplasms","volume":"1","author":"Tefferi","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0900","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","article-title":"Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0905","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/leu.2010.113","article-title":"IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0910","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/leu.2011.253","article-title":"IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F","volume":"26","author":"Tefferi","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0915","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0920","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2014.57","article-title":"CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0925","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR- vs JAK2- vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0930","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa1310523","article-title":"A pilot study of the telomerase inhibitor imetelstat for myelofibrosis","volume":"373","author":"Tefferi","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0935","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","article-title":"Targeted deep sequencing in primary myelofibrosis","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0940","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0945","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ajh.24978","article-title":"Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN Alliance study of 1,095 patients","volume":"93","author":"Tefferi","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0950","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1038\/s41375-018-0078-0","article-title":"U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0955","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ Version 2.0: Mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0960","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: Genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0965","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41375-018-0019-y","article-title":"Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0970","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/bjh.16380","article-title":"Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera","volume":"189","author":"Tefferi","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0975","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood-2006-12-062125","article-title":"Leukemic blasts in transformed JAK2 V617F\u2013positive myeloproliferative disorders are frequently negative for the JAK2 V617F mutation","volume":"110","author":"Theocharides","year":"2007","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0980","doi-asserted-by":"crossref","first-page":"106456","DOI":"10.1016\/j.leukres.2020.106456","article-title":"Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm","volume":"98","author":"Tremblay","year":"2020","journal-title":"Leuk. Res."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0985","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41375-018-0159-0","article-title":"ASXL1\/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF","volume":"33","author":"Triviai","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0990","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1038\/onc.2016.478","article-title":"Loss of p53 induces leukemic transformation in a murine model of JAK2 V617F-driven polycythemia vera","volume":"36","author":"Tsuruta-Kishino","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb0995","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb1000","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41408-019-0175-y","article-title":"Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model","volume":"9","author":"Vallapureddy","year":"2019","journal-title":"Blood Cancer J."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb1005","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb1010","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/leu.2014.100","article-title":"Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value","volume":"28","author":"Vannucchi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb1015","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/ajh.24973","article-title":"Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms","volume":"93","author":"Venton","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb1020","first-page":"1083","article-title":"CPI-0610, Bromodomain and extraterminal domain protein (BET) inhibitor, as \u2018add-on\u2019 to ruxolitinib (RUX), in advanced myelofibrosis patients with suboptimal response: update of MANIFEST Phase 2 study","volume":"4","author":"Verstovsek","year":"2020","journal-title":"HemaSphere"},{"issue":"Suppl. 15","key":"10.1016\/bs.ircmb.2021.02.008_bb1025","article-title":"BOREAS: a global phase 3 study of KRT-232, a first-in-class murine double minute 2 (MDM2) inhibitor in TP53WT relapsed\/refractory (R\/R) myelofibrosis (MF)","volume":"39","author":"Verstovsek","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb1030","series-title":"2021 European Hematology Association Congress (EHA2021)","article-title":"Pelabresib (CPI-0610) improved anemia associated with myelofibrosis: interim results from MANIFEST Phase 2 study","author":"Verstovsek","year":"2021"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb1035","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.celrep.2013.10.038","article-title":"Combined targeting of JAK2 and Bcl-2\/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors","volume":"5","author":"Waibel","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb1040","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/bloodadvances.2018022012","article-title":"Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells","volume":"2","author":"Wang","year":"2018","journal-title":"Blood Adv."},{"issue":"Suppl. 2","key":"10.1016\/bs.ircmb.2021.02.008_bb1045","article-title":"Driver mutation acquisition in utero and childhood followed by lifelong clonal evolution underlie myeloproliferative neoplasms","volume":"136","author":"Williams","year":"2020","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb1050","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1158\/1078-0432.CCR-18-4089","article-title":"Activation of JAK\/STAT signaling in megakaryocytes sustains myeloproliferation in vivo","volume":"25","author":"Woods","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb1055","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb1060","doi-asserted-by":"crossref","DOI":"10.4161\/jkst.25256","article-title":"The role of the JAK-STAT pathway and related signal cascades in telomerase activation during the development of hematologic malignancies","volume":"2","author":"Yamada","year":"2013","journal-title":"JAK-STAT"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb1065","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2017-06-789669","article-title":"Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies","volume":"131","author":"Yang","year":"2018","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb1070","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.mayocp.2017.05.010","article-title":"Leukemic transformation in myeloproliferative neoplasms","volume":"92","author":"Yogarajah","year":"2017","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb1075","doi-asserted-by":"crossref","first-page":"12484","DOI":"10.1038\/ncomms12484","article-title":"Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults","volume":"7","author":"Young","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/bs.ircmb.2021.02.008_bb1080","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1038\/leu.2016.114","article-title":"JAK2(V617F)-mutant megakaryocytes contribute to hematopoietic stem\/progenitor cell expansion in a model of murine myeloproliferation","volume":"30","author":"Zhan","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb1090","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/stem.2888","article-title":"JAK2 V617F megakaryocytes promote hematopoietic stem\/progenitor cell expansion in mice through thrombopoietin\/MPL signaling","volume":"36","author":"Zhang","year":"2018","journal-title":"Stem Cells"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb1085","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1182\/blood-2011-11-390252","article-title":"Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome","volume":"119","author":"Zhang","year":"2012","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.008_bb1095","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/2162-3619-1-15","article-title":"JAK2 V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines","volume":"1","author":"Zhao","year":"2012","journal-title":"Exper. Hematol. Oncol."}],"container-title":["International Review of Cell and Molecular Biology","Cellular and Molecular Aspects of Myeloproliferative Neoplasms \u2013 Part B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644821000137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644821000137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:31:54Z","timestamp":1762597914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1937644821000137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9780323899413"],"references-count":229,"URL":"https:\/\/doi.org\/10.1016\/bs.ircmb.2021.02.008","relation":{},"ISSN":["1937-6448"],"issn-type":[{"value":"1937-6448","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}